For patients with HIV/AIDS, highly active antiretroviral therapy (HAART) is currently the only effective therapy for progressive multifocal leukoencephalopathy (PML), a viral-induced demyelinating disease caused by polyomavirus JC. Immune reconstitution inflammatory syndrome (IRIS) following initiation of HAART can cause paradoxical clinical deterioration in patients with established PML. Because the onset of PML follows soon after initiation of HAART in some cases (unmasking), we investigated the role IRIS plays in unmasked PML. We reviewed records of 20 PML cases seen from 1997-2006 at the UCSD HIV primary care clinic. Eight cases presented with PML symptoms within 6 months of initiating HAART (referred to hereafter as unmasked PML), six patients were diagnosed with PML before initiating HAART, and six were diagnosed more than 6 months after starting HAART. Patients with unmasked PML constituted 40% of our series, had relatively long survival, and commonly (50%) had lesions exclusively in the posterior fossa, a localization not previously reported with such a high prevalence. Only 3 of the 8 patients with unmasked PML had IRIS reactions as evidenced by contrast enhancement around lesions on MRI, suggesting that IRIS is not necessary for the pathogenesis of this syndrome.
Introduction
The incidence of progressive multifocal leukoencephalopathy (PML), a viral-induced demyelinating disease caused by reactivation of the polyomavirus JC (JCV), has increased markedly in the last three decades. The primary cause of the immune suppression that enables JCV to replicates is HIV (Holman et al., 1991; Tyler, 2003) , but iatrogenic immunosuppression (primarily for organ transplantation) has also played a minor role (Krupp et al., 1985; Shitrit et al., 2005) . Molecular evidence suggests the HIV virus also may promote the development of PML via HIV-1 Tat protein induction of JCV late gene expression (Chowdhury et al., 1990) . Both mechanisms may contribute to the increased rates of PML in the HIV epidemic compared to the pre-HIV era and in those patients who fail HAART.
Before the era of HAART, PML usually portended death within months due to a lack of available therapy for either HIV or PML. Currently, restoration of immune function by HAART is the only effective therapy for PML in patients with HIV/AIDS. For many patients, HAART arrests the progressive neurologic dysfunction caused by PML and prolongs survival, but does not fully restore lost function (Antinori et al., 2003; Cinque et al., 1998 Cinque et al., , 2001 De Luca et al., 1998; Miralles et al., 1998 Miralles et al., , 2001 ). Also, while the incidence of other CNS opportunistic infections has significantly decreased in the HAART era, the incidence of PML has decreased to a lesser extent (Engsig et al., 2008; Ammassari et al., 2000; Sacktor et al., 2001) . It is unclear why the incidence of PML has decreased only slightly during the HAART era, but the numerous cases of PML that developed after the initiation of HAART (as discussed below) may contribute to the current incidence rate of PML.
PML occurs in both HAART-naïve and HAART-treated patients, and the clinical characteristics of PML may differ among these patient groups. For instance, patients developing PML soon after successfully initiating HAART have significantly lower plasma levels of HIV than PML patients who are either off or failing HAART (Cinque et al., 2003) . Some of these cases of PML appear to represent immune reconstitution inflammatory syndrome (IRIS), an increased inflammatory response to an opportunistic infection that occurs soon after initiating successful HAART. Defined by Shelburne et al. in 2002, immune reconstitution inflammatory syndrome (IRIS) has four criteria: 1) the patient has a diagnosis of AIDS; 2) treatment with HAART leads to an increased CD4 cell count and decreased HIV-1 viral load; 3) symptoms consistent with an infectious or inflammatory condition occur during HAART treatment; and 4) the symptoms cannot be explained by a newly acquired infection, the expected clinical course of a previous known infection or by side effects of therapy (Shelburne et al., 2002) . PML IRIS manifests as a paradoxical clinical deterioration with evidence of JCV infection of the CNS, and PML lesions on neuroimaging often present with contrast enhancement representing perilesional inflammation. PML onset can occur soon after initiation of HAART, supporting a possible role of IRIS in unmasking subclinical PML. Clear examples of this syndrome have been documented in the literature (Cinque et al., 2003; Gray et al., 2005; Manzardo et al., 2005; Tan et al., Journal of Neuroimmunology 219 (2010) [100] [101] [102] [103] [104] 
